Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$94 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
3.3
Industry P/E
--
EV/EBITDA
-3.8
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-3.6
Face value
--
Shares outstanding
37,572,200
CFO
$-200.19 Mln
EBITDA
$-252.81 Mln
Net Profit
$-245.02 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Biomea Fusion (BMEA)
| -35.7 | 53.0 | 1.4 | -43.7 | -33.4 | -- | -- |
|
BSE Sensex
| 3.7 | -1.6 | 9.6 | 5.9 | 14.3 | 19.1 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
|---|---|---|---|
|
Biomea Fusion (BMEA)
| -73.0 | 72.2 | 13.2 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Biomea Fusion (BMEA)
|
2.5 | 93.9 | 1.2 | -128.6 | -8,441.6 | -245.7 | -- | 3.3 |
| 50.9 | 8,079.8 | 1,208.8 | 131.7 | 13.4 | 6.3 | 62.1 | 3.9 | |
| 128.1 | 8,274.0 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 151.3 | 7,421.9 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 53.8 | 10,499.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.3 | |
| 41.6 | 11,298.3 | 2,298.9 | 643.6 | 35.4 | 29.2 | 19.1 | 5.5 | |
| 300.1 | 8,688.9 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.4 | 14.6 | |
| 26.8 | 10,732.1 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.1 | |
| 124.4 | 12,288.6 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.4 | 4.9 | |
| 284.9 | 12,470.6 | 2,994.1 | 1,210.7 | 51.4 | 18.8 | 12.9 | 2.2 |
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. It's lead product... candidate is icovamenib, is designed to be a bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair, it is used for the treatment of menin regulated or dependent diseases such as type 1 and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California. Address: 900 Middlefield Road, Redwood City, CA, United States, 94063 Read more
Co-Founder, Chairman & CEO
Mr. Thomas Andrew Butler
Co-Founder, Chairman & CEO
Mr. Thomas Andrew Butler
Headquarters
Redwood City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Biomea Fusion Inc (BMEA) stood at $ 75 Mln as on 31-Mar-25
The share price of Biomea Fusion Inc (BMEA) is $2.49 (NASDAQ) as of 13-Jun-2025 11:42 EDT. Biomea Fusion Inc (BMEA) has given a return of -33.37% in the last 3 years.
Biomea Fusion Inc (BMEA) has a market capitalisation of $ 94 Mln as on 12-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Biomea Fusion Inc (BMEA) is 3.27 times as on 12-Jun-2025, a 26% premium to its peers’ median range of 2.59 times.
Since, TTM earnings of Biomea Fusion Inc (BMEA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Biomea Fusion Inc (BMEA) and enter the required number of quantities and click on buy to purchase the shares of Biomea Fusion Inc (BMEA).
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. It's lead product candidate is icovamenib, is designed to be a bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair, it is used for the treatment of menin regulated or dependent diseases such as type 1 and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California. Address: 900 Middlefield Road, Redwood City, CA, United States, 94063
The CEO & director of Mr. Thomas Andrew Butler. is Biomea Fusion Inc (BMEA), and CFO & Sr. VP is Mr. Thomas Andrew Butler.
There is no promoter pledging in Biomea Fusion Inc (BMEA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,247
|
|
|
1,229
|
|
|
1,130
|
|
|
1,073
|
|
|
1,050
|
|
|
869
|
|
|
827
|
|
|
808
|
|
|
742
|
| Biomea Fusion Inc. (BMEA) | Ratios |
|---|---|
|
Return on equity(%)
|
-245.68
|
|
Operating margin(%)
|
-8441.64
|
|
Net Margin(%)
|
-10543.2
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Biomea Fusion Inc (BMEA) was $0 Mln.
$-0.12
(
